





Name : MRS.SASIKALA G TID/SID : UMR2599170/ 29168116 Age / Gender : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Ref.By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Req.No : BIL5396703 Reported on : 08-Mar-2025 / 15:54 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

DEPARTMENT OF CLINICAL PATHOLOGY		
Investigation	Observed Value	Biological Reference Intervals
Physical Examination	- CDSCIVED VAIDE	Biological Helerende intervale
Colour	Pale Yellow	Straw to Yellow
Method:Physical	r alo rollott	
Appearance	Clear	Clear
Method:Physical		
Chemical Examination		
Reaction and pH	6.0	4.6-8.0
Method:pH- Methyl red & Bromothymol blue		
Specific gravity	1.005	1.003-1.035
Method:Bromothymol Blue		
Protein	Negative	Negative
Method:Tetrabromophenol blue		
Glucose	Negative	Negative
Method:Glucose oxidase/Peroxidase		
Blood	Negative	Negative
Method:Peroxidase		
Ketones	Negative	Negative
Method:Sodium Nitroprusside Method		
Bilirubin	Negative	Negative
Method:Dichloroanilinediazonium		
Leucocytes	Negative	Negative
Method:3 hydroxy5 phenylpyrrole + diazonium		
Nitrites	Negative	Negative
Method:Diazonium + 1,2,3,4 tetrahydrobenzo (h) quii 3-ol	nolin	
Urobilinogen	0.2	0.2-1.0 mg/dl
Method:Dimethyl aminobenzaldehyde		
Microscopic Examination		
Pus cells (leukocytes)	0-1	2 - 3 /hpf
Method:Microscopy		
Epithelial cells Method:Microscopy	0-1	2 - 5 /hpf
RBC (erythrocytes)	Absent	Absent
Method:Microscopy		
Casts	Absent	Occasional hyaline casts may
Method:Microscopy		,







: MRS.SASIKALA G TID/SID Name Age / Gender

Registered on: 08-Mar-2025 / 08:07 AM

:UMR2599170/ 29168116

: ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM Ref.By

: 50 Years / Female

Reported on : 08-Mar-2025 / 15:54 PM

Rea.No : BIL5396703

Reference

: Arcofemi Health Care Ltd -

Crystals

Others

Absent

Phosphate, oxalate, or urate crystals may

be seen

Method:Microscopy

Nil

Nil

Method:Microscopy

#### Method: Semi Quantitative test ,For CUE

Reference: Godkar Clinical Diagnosis and Management by Laboratory Methods, First South Asia edition. Product kit literature.

**TEST REPORT** 

#### Interpretation:

The complete urinalysis provides a number of measurements which look for abnormalities in the urine. Abnormal results from this test can be indicative of a number of conditions including kidney disease, urinary tract infecation or elevated levels of substances which the body is trying to remove through the urine. A urinalysis test can help identify potential health problems even when a person is asymptomatic. All the abnormal results are to be correlated clinically.

\* Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore

--- End Of Report ---

Dr.Kavya S N **Consultant Pathologist** KMC NO: 84851









Name Age / Gender Ref.By Reg.No

: MRS.SASIKALA G

TID/SID

:UMR2599170/ 29168117

: 50 Years / Female

Registered on: 08-Mar-2025 / 08:07 AM

: ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Reported on : 08-Mar-2025 / 13:51 PM

: BIL5396703

Reference **TEST REPORT** 

: Arcofemi Health Care Ltd -

### **DEPARTMENT OF HEMATOPATHOLOGY**

# **Blood Grouping ABO And Rh Typing**

Parameter Results

В Blood Grouping (ABO)

Rh Typing (D) **NEGATIVE** 

Note Confirmed by gel card method.

Method: Hemagglutination Tube Method by Forward & Reverse Grouping

Reference: Kit literature

Interpretation: The ABO grouping and Rh typing test determines blood type grouping (A,B, AB, O) and the Rh factor (positive or negative). A person's blood type is based on the presence or absence of certain antigens on the surface of their red blood cells and certain antibodies in the plasma. A,B,H antigens are not fully developed at birth, increase gradually in strength and become fully expressed around 1 year of age. It is mandatory to repeat blood grouping at/after one year of age for new born babies &/or done on cord blood

Note: All individuals carry other blood group system antigens in addition to ABO and Rh. Antibody screening is recommended to all individuals before blood transfusion to detect any unexpected antibodies.

--- End Of Report ---

Dr.Kavya S N **Consultant Pathologist** KMC NO: 84851

<sup>\*</sup> Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore







Name Age / Gender Ref.By

: MRS.SASIKALA G

TID/SID

:UMR2599170/ 29168117

: 50 Years / Female

: ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Registered on: 08-Mar-2025 / 08:07 AM

: BIL5396703 Req.No

Reported on : 08-Mar-2025 / 10:28 AM

**TEST REPORT** 

Reference

: Arcofemi Health Care Ltd -

# **DEPARTMENT OF HEMATOPATHOLOGY**

# **Erythrocyte Sedimentation Rate (ESR)**

Investigation	Observed Value	Biological Reference Intervals
ESR 1st Hour	33	<=20 mm/hour

Method:Modified Westergren

# Complete Blood Count (CBC)

Investigation	Observed Value	Biological Reference Interval
Hemoglobin	11.2	11.5-16.0 g/dL
Method:Spectrophotometry Packed Cell Volume	33.2	34-48 %
Method:Derived from Impedance		
Red Blood Cell Count. Method:Impedance Variation	4.13	4.2-5.4 Mill/Cumm
Mean Corpuscular Volume Method:Derived from Impedance	80.3	78-100 fL
Mean Corpuscular Hemoglobin Method:Derived from Impedance	27.1	27-32 pg
Mean Corpuscular Hemoglobin Concentration  Method:Derived from Impedance	33.8	31.5-36 g/dL
Red Cell Distribution Width - CV  Method:Derived from Impedance	13.4	11.5-16.0 %
Red Cell Distribution Width - SD  Method:Derived from Impedance	38.1	39-46 fL
Total WBC Count.  Method:Impedance Variation	6010	4000-11000 cells/cumm
Neutrophils Method:Impedance Variation, Flowcytometry	43.1	40-75 %
Method.Impedance variation, r lowcytometry		
Lymphocytes Method:Microscopy	45.6	20-45 %
Eosinophils	4.3	01-06 %
Method:Impedance Variation,Method_Desc= Flow Cytometry		
Monocytes	6.8	01-10 %
Method:Impedance Variation, Flowcytometry	• •	00.00.00
Basophils.  Method:Impedance Variation,Method_Desc= Flow Cytometry	0.2	00-02 %







Name : MRS.SASIKALA G TID/SID : UMR2599170/ 29168117

Age / Gender : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Ref.By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Req.No : BIL5396703 Reported on : 08-Mar-2025 / 10:28 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

Absolute Neutrophils Count.  Method:Calculated	2590	1500-6600 cells/cumm
Absolute Lymphocyte Count Method:Calculated	2741	1500-3500 cells/cumm
Absolute Eosinophils count.  Method:Calculated	258	40-440 cells/cumm
Absolute Monocytes Count.  Method:Calculated	409	<1000 cells/cumm
Absolute Basophils count.  Method:Calculated	12	<200 cells/cumm
Platelet Count.  Method:Impedance Variation	2.17	1.4-4.4 lakhs/cumm
Mean Platelet Volume.  Method:Derived from Impedance	7.5	8.0-13.3 fL
Plateletcrit. Method:Derived from Impedance	0.16	0.18-0.28 %

Method: Automated Hematology Analyzer, Microscopy

Reference: Dacie and Lewis Practical Hematology, 12th Edition

**Interpretation:** A Complete Blood Picture (CBP) is a screening test which can aid in the diagnosis of a variety of conditions and diseases such as anemia, leukemia, bleeding disorders and infections. This test is also useful in monitoring a person's reaction to treatment when a condition which affects blood cells has been diagnosed. All the abnormal results are to be correlated clinically.

--- End Of Report ---

Konda

Dr.Kavya S N Consultant Pathologist KMC NO : 84851

<sup>\*</sup> Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore







Name
Age /
Ref.By
Req.No

: MRS.SASIKALA G TID/SID : UMR2599170/ 29168119F : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Age / Gender : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Ref.By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM Reg.No : BIL5396703 Reported on : 08-Mar-2025 / 11:24 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

# DEPARTMENT OF CLINICAL CHEMISTRY I Blood Urea Nitrogen (BUN) Observed Value Biological Reference Interval 8.7 6-20 mg/dL

Method:Kinetic, Urease - GLDH, Calculated

Investigation

Blood Urea Nitrogen.

**Interpretation:** Urea is a waste product formed in the liver when protein is metabolized. Urea is released by the liver into the blood and is carried to the kidneys, where it is filtered out of the blood and released into the urine. Since this is a continuous process, there is usually a small but stable amount of urea nitrogen in the blood. However, when the kidneys cannot filter wastes out of the blood due to disease or damage, then the level of urea in the blood will rise. The blood urea nitrogen (BUN) evaluates kidney function in a wide range of circumstances, to diagnose kidney disease, and to monitor people with acute or chronic kidney dysfunction or failure. It also may be used to evaluate a person's general health status as well.

Reference: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics

#### Creatinine. Serum

Investigation	Observed Value	Biological Reference Interval
Creatinine.	0.7	0.5-1.1 mg/dL
Method:Spectrophotometry Jaffe - IDMS Traceable		

#### Interpretation:

Creatinine is a nitrogenous waste product produced by muscles from creatine. Creatinine is majorly filtered from the blood by the kidneys and released into the urine, so serum creatinine levels are usually a good indicator of kidney function. Serum creatinine is more specific and more sensitive indicator of renal function as compared to BUN because it is produced from muscle at a constant rate and its level in blood is not affected by protein catabolism or other exogenous products. It is also not reabsorbed and very little is secreted by tubules making it a reliable marker. Serum creatinine levels are increased in pre renal, renal and post renal azotemia, active acromegaly and gigantism. Decreased serum creatinine levels are seen in pregnancy and increasing age.

Biological reference interval changed; Reference: Tietz Textbook of Clinical Chemistry & Molecular Diagnostics, Fifth Edition.

#### Glucose Fasting (FBS)

1116	<u> </u>	<u>,                                      </u>
Investigation	Observed Value	Biological Reference Interval
Glucose Fasting Method:Hexokinase	87	Normal: <100 mg/dL Impaired FG: 100-125 mg/dL Diabetes mellitus: >/=126 mg/dL

**Interpretation:** It measures the Glucose levels in the blood with a prior fasting of 9-12 hours. The test helps screen a symptomatic/ asymptomatic person who is at risk for Diabetes. It is also used for regular monitoring of glucose levels in people with Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2022







Name : MRS.SASIKALA G TID/SID : UMR2599170/ 29168118

Age / Gender : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Ref.By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Req.No : BIL5396703 Reported on : 08-Mar-2025 / 11:14 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

# **Glucose Post Prandial (PPBS)**

Investigation	Observed Value	Biological Reference Interval
Glucose Post Prandial Method:Hexokinase	120	Normal : <140 mg/dL Impaired PG: 140-199 mg/dL Diabetes mellitus: >/=200 mg/dL

**Interpretation:** This test measures the blood sugar levels 2 hours after a normal meal. Abnormally high blood sugars 2 hours after a meal reflect that the body is not producing sufficient insulin which is indicative of Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2020.

## Glycosylated Hemoglobin (HbA1C)

Investigation	Observed Value	Biological Reference Interval
Glycosylated Hemoglobin (HbA1c) Method:High-Performance Liquid Chromatography	5.0	Non-diabetic: <= 5.6 % Pre-diabetic: 5.7 - 6.4 % Diabetic: >= 6.5 %
Estimated Average Glucose (eAG)	97	mg/dL %

**Interpretation**: It is an index of long-term blood glucose concentrations and a measure of the risk for developing microvascular complications in patients with diabetes. Absolute risks of retinopathy and nephropathy are directly proportional to the mean HbA1c concentration. In persons without diabetes, HbA1c is directly related to risk of cardiovascular disease.

In known diabetic patients, HbA1c can be considered as a tool for monitoring the glycemic control.

Excellent Control - 6 to 7 %,

Fair to Good Control - 7 to 8 %, Unsatisfactory Control - 8 to 10 %

and Poor Control - More than 10 %.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2018.

#### **Bun/Creatinine Ratio**

Investigation	Observed Value		
BUN/Creatinine Ratio Method:Calculated	12.4	12-16	
Blood Urea Nitrogen.  Method:Kinetic, Urease - GLDH, Calculated	8.7	6-20 mg/dL	
Urea. Method:Kinetic UV	18.7	12.8-42.8 mg/dL	
Creatinine.  Method:Spectrophotometry .laffe - IDMS Traceable	0.7	0.5-1.1 mg/dL	





Name Age / Gender Ref.By

: MRS.SASIKALA G

TID/SID

:UMR2599170/ 29168118

: 50 Years / Female

: ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Registered on: 08-Mar-2025 / 08:07 AM

Req.No : BIL5396703

Reported on : 08-Mar-2025 / 11:14 AM

**TEST REPORT** 

Reference : Arcofemi Health Care Ltd -

#### Reference:

A Manual of Laboratory Diagnostic Tests. Edition 7, Lippincott Williams and Wilkins, By Frances Talaska Fischbach, RN, BSN, MSN, and Marshall Barnett Dunning 111, BS, MS, Ph.D.

\* Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore

--- End Of Report ---









Name : MRS.SASIKALA G TID/SID : UMR2599170/ 29168118

Age / Gender : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Ref.By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Reg.No : BIL5396703

Reported on : 08-Mar-2025 / 11:14 AM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I Lipid Profile** Observed Value Investigation Biological Reference Interval 157 Desirable: < 200 mg/dL **Total Cholesterol** Borderline: 200-239 mg/dL Method:Spectrophotometry, CHOD - POD High: >/= 240 mg/dL 74 Optimal: >=60 mg/dL **HDL Cholesterol** Borderline: 40-59 ma/dL Method:Spectrophotometry, Direct Measurement High Risk <40 mg/dL 83 Optimal: <130 mg/dL **Non HDL Cholesterol** Above Optimal: 130-159 mg/dL Method:Calculated Borderline: 160-189 mg/dL High Risk: 190-219 mg/dL Very high Risk: >=220 mg/dL Optimum: <100 ma/dL 65.6 **LDL Cholesterol** Near/above optimum: 100-129 mg/dL Method:Calculated Borderline: 130-159 mg/dL High: 160-189 mg/dL Very high: >/=190 mg/dL 17.40 <30 ma/dL **VLDL Cholesterol** Method:Calculated 2.12 Optimal: <3.3 **Total Cholesterol/HDL Ratio** Low Risk: 3.4-4.4 Method:Calculated Average Rsik: 4.5-7.1 Moderate Risk: 7.2-11.0 High Risk: >11.0 0.89 Optimal: 0.5-3.0 LDL/HDL Ratio Borderline: 3.1-6.0 Method:Calculated High Risk: >6.0 Normal:<150 mg/dL 87 **Trialvcerides** Borderline: 150-199 mg/dL Method:Spectrophotometry, Enzymatic - GPO/POD High: 200-499 mg/dL Very high: >/=500 mg/dL mg/dl#

Interpretation: Lipids are fats and fat-like substances which are important constituents of cells and are rich sources of energy. A lipid profile typically includes total cholesterol, high density lipoproteins (HDL), low density lipoprotein (LDL), chylomicrons, triglycerides, very low density lipoproteins (VLDL), Cholesterol/HDL ratio .The lipid profile is used to assess the risk of developing a heart disease and to monitor its treatment. The results of the lipid profile are evaluated along with other known risk factors associated with heart disease to plan and monitor treatment. Treatment options require clinical correlation.Reference: Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2001.

<sup>\*</sup> Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore





Name : MRS.SASIKALA G TID/SID : UMR2599170/

Age / Gender : 50 Years / Female Registered on : 08-Mar-2025 / 08:07 AM

Ref.By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : Req.No : BIL5396703 Reported on :

TEST REPORT Reference : Arcofemi Health Care Ltd -





Name Age / Gender : MRS.SASIKALA G

TID/SID

:UMR2599170/ 29168118

: 50 Years / Female

Registered on: 08-Mar-2025 / 08:07 AM

Ref.By

: ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Reported on : 08-Mar-2025 / 11:14 AM

Rea.No : BIL5396703

**TEST REPORT** 

Reference : Arcofemi Health Care Ltd -

# **DEPARTMENT OF CLINICAL CHEMISTRY I**

# **Liver Function Test (LFT)**

Investigation	Result	Biological Reference Interval
Total Bilirubin. Method:Spectrophotometry, Diazo method	0.44	Neonates: <=15.0 mg/dL Adults: <=1.2 mg/dL
Direct Bilirubin.  Method:Spectrophotometry, Diazo method	0.26	<=0.30 mg/dL
Indirect Bilirubin. Method:Calculated	0.18	Neonates: <= 14.7 mg/dL Adults: <= 1.0 mg/dL
Alanine Aminotransferase ,(ALT/SGPT)  Method: IFCC without pyridoxal phosphate activation	12	<=33 U/L
Aspartate Aminotransferase,(AST/SGOT)  Method: IFCC without pyridoxal phosphate activation	13	<=32 U/L
ALP (Alkaline Phosphatase).  Method:Spectrophotometry , IFCC	100	35-104 U/L
Gamma GT.  Method:Spectrophotometry , IFCC	10	<40 U/L
Total Protein.  Method:Spectrophotometry, Biuret	7.4	6.4-8.3 g/dL
Albumin.  Method:Spectrophotometry, Bromcresol Green	4.1	3.5-5.2 g/dL
Globulin.  Method:Spectrophotometry, Bromcresol Green	3.30	2.0-3.5 g/dL
A/GRatio.  Method:Calculated	1.24	1.1-2.5

Interpretation: Liver functions tests help to identify liver disease, its severity, and its type. Generally these tests are performed in combination, are abnormal in liver disease, and the pattern of abnormality is indicative of the nature of liver disease. An isolated abnormality of a single liver function test usually means a non-hepatic cause. If several liver function tests are simultaneously abnormal, then hepatic etiology is likely.

--- End Of Report ---

<sup>\*</sup> Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore









: MRS.SASIKALA G TID/SID :UMR2599170/ 29168118 Name Age / Gender Registered on: 08-Mar-2025 / 08:07 AM : 50 Years / Female : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM Ref.By Reported on : 08-Mar-2025 / 11:10 AM Rea.No : BIL5396703 Reference : Arcofemi Health Care Ltd -

**DEPARTMENT OF CLINICAL CHEMISTRY I** 

**TEST REPORT** 

Thyroid Profile (T3,T4,TSH)		
Investigation	Observed Value	Biological Reference Interval
Triiodothyronine Total (T3) Method:ECLIA	1.03	0.80-2.00 ng/mL Pregnancy: 1st Trimester: 0.9 -2.5 ng/mL 2nd Trimester: 1.00 - 2.4 ng/mL 3rd Trimester 0.9-2.4 ng/mL Note: Biological Reference Ranges are changed due to change in method of testing.
Thyroxine Total (T4) Method:ECLIA	7.78	4.6-12.0 μg/dL Pregnancy: 1st Trimester: 4.4 - 11.5 μg/dL 2nd Trimester: 4.9 - 12.2 μg/dL 3rd Trimester: 5.1 - 13.2μg/dL Note: Biological Reference Ranges are changed due to change in method of testing.
Thyroid Stimulating Hormone (TSH)  Method:ECLIA	2.70	0.27-4.20 μIU/mL Pregnancy: 1st Trimester: 0.1 - 3.0 μIU/mL 2nd Trimester: 0.4 - 3.3 μIU/mL 3rd Trimester: 0.4 - 3.8 μIU/mL Note: Biological Reference Ranges are changed due to change in method of testing.

Interpretation: A thyroid profile is used to evaluate thyroid function and/or help diagnose hypothyroidism and hyperthyroidism due to various thyroid disorders. T4 and T3 are hormones produced by the thyroid gland. They help control the rate at which the body uses energy, and are regulated by a feedback system. TSH from the pituitary gland stimulates the production and release of T4 (primarily) and T3 by the thyroid. Most of the T4 and T3 circulate in the blood bound to protein. A small percentage is free (not bound) and is the biologically active form of the hormones.

Reference: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, Carl A. Burtis, David E. Bruns.

--- End Of Report ---



<sup>\*</sup> Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore







Name Age / Gender Ref.By

: MRS.SASIKALA G

TID/SID

:UMR2599170/ 29168118

: 50 Years / Female

Registered on: 08-Mar-2025 / 08:07 AM

: ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Collected on : 08-Mar-2025 / 08:12 AM

Reported on : 08-Mar-2025 / 11:14 AM

Rea.No : BIL5396703

> Reference **TEST REPORT**

: Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I** Uric Acid, Serum Observed Value Biological Reference Interval Investigation 6.2 2.4-5.7 mg/dL Uric Acid. Method:Enzymatic

Interpretation: It is the major product of purine catabolism. Hyperuricemia can result due to increased formation or decreased excretion of uric acid which can be due to several causes like metabolic disorders, psoriasis, tissue hypoxia, pre-eclampsia, alcohol, lead poisoning, acute or chronic kidney disease, etc. Hypouricemia may be seen in severe hepato cellular disease and defective renal tubular reabsorption of uric acid.

--- End Of Report ---





<sup>\*</sup> Sample processed at Regional Reference Laboratory, Tenet Diagnostics, Bangalore





: Mrs . SASIKALA G : UMR2599170 Name TID

Age/Gender : 50 Years/Female Registered On: 08-Mar-2025 08:07 AM Ref By : ARCOFEMI HEALTH CARE LTD - MEDI WHEELS Reported On : 08-Mar-2025 12:11 PM Reg.No : BIL5396703

Reference : Arcofemi Health Care Ltd

- Medi Whe

# X-Ray Chest PA View

Lung fields appear normal.

Cardiac size is within normal limits.

Aorta and pulmonary vasculature is normal.

Bilateral domes of diaphragm and costophrenic angles are normal.

Visualised bones and soft tissues appear normal.

**IMPRESSION:** 

Normal study.

\*\*\* End Of Report \*\*\*

Dr Thilak K S Consultant Radiologist

Thilak. K.S.